Published in S Afr Med J on June 01, 2006
Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science (2010) 35.19
Effectiveness of COL-1492, a nonoxynol-9 vaginal gel, on HIV-1 transmission in female sex workers: a randomised controlled trial. Lancet (2002) 11.02
HIV infection and tuberculosis in South Africa: an urgent need to escalate the public health response. Lancet (2009) 6.96
Drug concentrations after topical and oral antiretroviral pre-exposure prophylaxis: implications for HIV prevention in women. Lancet (2011) 6.91
Who infects whom? HIV-1 concordance and discordance among migrant and non-migrant couples in South Africa. AIDS (2003) 4.87
HIV prevention transformed: the new prevention research agenda. Lancet (2011) 4.23
Tenofovir Gel for the Prevention of Herpes Simplex Virus Type 2 Infection. N Engl J Med (2015) 3.64
Preliminary outcomes of a paediatric highly active antiretroviral therapy cohort from KwaZulu-Natal, South Africa. BMC Pediatr (2007) 2.67
Stabilizing HIV prevalence masks high HIV incidence rates amongst rural and urban women in KwaZulu-Natal, South Africa. Int J Epidemiol (2010) 2.53
Antiretroviral prophylaxis: a defining moment in HIV control. Lancet (2011) 2.17
Dual HIV-1 infection associated with rapid disease progression. Lancet (2004) 2.17
Vertical T cell immunodominance and epitope entropy determine HIV-1 escape. J Clin Invest (2012) 2.05
Plasma cytokine levels during acute HIV-1 infection predict HIV disease progression. AIDS (2010) 1.94
Enrolling adolescents in research on HIV and other sensitive issues: lessons from South Africa. PLoS Med (2006) 1.90
A model designed to enhance informed consent: experiences from the HIV prevention trials network. Am J Public Health (2005) 1.89
AIDS research must link to local policy. Nature (2010) 1.81
Patients' readiness to start highly active antiretroviral treatment for HIV. BMJ (2005) 1.54
A pilot study of once-daily antiretroviral therapy integrated with tuberculosis directly observed therapy in a resource-limited setting. J Acquir Immune Defic Syndr (2004) 1.42
Relationship between levels of inflammatory cytokines in the genital tract and CD4+ cell counts in women with acute HIV-1 infection. J Infect Dis (2008) 1.42
Epidemiological impact of tenofovir gel on the HIV epidemic in South Africa. J Acquir Immune Defic Syndr (2011) 1.31
Practice brief: adolescents and HIV clinical trials: ethics, culture, and context. J Assoc Nurses AIDS Care (2007) 1.29
HIV incidence in young girls in KwaZulu-Natal, South Africa--public health imperative for their inclusion in HIV biomedical intervention trials. AIDS Behav (2012) 1.26
Development of methods for cross-sectional HIV incidence estimation in a large, community randomized trial. PLoS One (2013) 1.24
HIV-prevention science at a crossroads: advances in reducing sexual risk. Curr Opin HIV AIDS (2009) 1.18
Recruitment of high risk women for HIV prevention trials: baseline HIV prevalence and sexual behavior in the CAPRISA 004 tenofovir gel trial. Trials (2011) 1.15
Contraceptive choices, pregnancy rates, and outcomes in a microbicide trial. Obstet Gynecol (2011) 1.13
Mannose-rich glycosylation patterns on HIV-1 subtype C gp120 and sensitivity to the lectins, Griffithsin, Cyanovirin-N and Scytovirin. Virology (2010) 1.13
Duffy-null-associated low neutrophil counts influence HIV-1 susceptibility in high-risk South African black women. Clin Infect Dis (2011) 1.09
High prevalence of abnormal Pap smears among young women co-infected with HIV in rural South Africa - implications for cervical cancer screening policies in high HIV prevalence populations. S Afr Med J (2007) 1.09
Brain incorporation of [11C]arachidonic acid in young healthy humans measured with positron emission tomography. J Cereb Blood Flow Metab (2002) 1.07
Utilizing nucleic acid amplification to identify acute HIV infection. AIDS (2007) 1.07
Co-enrollment in multiple HIV prevention trials - experiences from the CAPRISA 004 Tenofovir gel trial. Contemp Clin Trials (2011) 1.04
Reduced antituberculosis drug concentrations in HIV-infected patients who are men or have low weight: implications for international dosing guidelines. Antimicrob Agents Chemother (2012) 1.04
Ethics guidance for HIV prevention trials. BMJ (2003) 1.03
Association of TRIM22 with the type 1 interferon response and viral control during primary HIV-1 infection. J Virol (2010) 1.02
Impact of an adherence intervention on the effectiveness of tenofovir gel in the CAPRISA 004 trial. AIDS Behav (2014) 1.00
CAPRISA 004 tenofovir microbicide trial: no impact of tenofovir gel on the HIV transmission bottleneck. J Infect Dis (2012) 0.99
Changes in Natural Killer cell activation and function during primary HIV-1 Infection. PLoS One (2013) 0.96
Ethical challenges in international HIV prevention research. Account Res (2004) 0.94
Safety of tenofovir gel, a vaginal microbicide, in South African women: results of the CAPRISA 004 Trial. Antivir Ther (2012) 0.94
Knowledge and acceptability of HAART among TB patients in Durban, South Africa. AIDS Care (2005) 0.93
Time for gender mainstreaming in editorial policies. J Int AIDS Soc (2011) 0.89
Management of steroid-resistant focal segmental glomerulosclerosis in children using tacrolimus. Am J Nephrol (2006) 0.88
Disclosure of HIV status: Experiences of Patients Enrolled in an Integrated TB and HAART Pilot Programme in South Africa. Afr J AIDS Res (2009) 0.88
Sustainability of task-shifting for antiretroviral treatment. Lancet (2012) 0.87
Trial participation disclosure and gel use behavior in the CAPRISA 004 tenofovir gel trial. AIDS Care (2014) 0.87
Single low-dose ceftriaxone for the treatment of gonococcal ophthalmia--implications for the national programme for the syndromic management of sexually transmitted diseases. S Afr Med J (2002) 0.87
No evidence for selection of HIV-1 with enhanced gag-protease or Nef function among breakthrough infections in the CAPRISA 004 tenofovir microbicide trial. PLoS One (2013) 0.86
In vivo muscarinic 2 receptor imaging in cognitively normal young and older volunteers. Synapse (2003) 0.86
HIV infection in high school students in rural South Africa: role of transmissions among students. AIDS Res Hum Retroviruses (2014) 0.86
Risk Factors for HIV Acquisition in High Risk Women in a Generalised Epidemic Setting. AIDS Behav (2015) 0.85
Initiating antiretrovirals during tuberculosis treatment: a drug safety review. Expert Opin Drug Saf (2011) 0.85
Antiretroviral prophylaxis for HIV prevention reaches a key milestone. Lancet (2012) 0.85
Apolipoprotein E polymorphism and outcome after closed traumatic brain injury: influence of ethnic and regional differences. J Neurosurg (2003) 0.85
Apnea and its possible relationship to immunization in ex-premature infants. Vaccine (2008) 0.84
Assessing adherence in the CAPRISA 004 tenofovir gel HIV prevention trial: results of a nested case-control study. AIDS Behav (2014) 0.83
The spectrum of chronic kidney disease (stages 2-5) in KwaZulu-Natal, South Africa. Pediatr Nephrol (2008) 0.83
Identification of broadly neutralizing antibody epitopes in the HIV-1 envelope glycoprotein using evolutionary models. Virol J (2013) 0.82
HIV incidence estimates are key to understanding the changing HIV epidemic in South Africa. S Afr Med J (2007) 0.81
Women with pregnancies had lower adherence to 1% tenofovir vaginal gel as HIV preexposure prophylaxis in CAPRISA 004, a phase IIB randomized-controlled trial. PLoS One (2013) 0.81
Broadly neutralizing antibody specificities detected in the genital tract of HIV-1 infected women. AIDS (2016) 0.80
Changes to antiretroviral drug regimens during integrated TB-HIV treatment: results of the SAPiT trial. Antivir Ther (2013) 0.80
When "happy" means "sad": neuropsychological evidence for the right prefrontal cortex contribution to executive semantic processing. Neuropsychologia (2006) 0.79
HIV prevention and treatment research in sub-Saharan Africa: where are the adolescents? AIDS (2006) 0.78
HIV prevalence among high school learners - opportunities for school-based HIV testing programmes and sexual reproductive health services. World Health Popul (2012) 0.78
HIV-positive status disclosure in patients in care in rural South Africa: implications for scaling up treatment and prevention interventions. AIDS Behav (2015) 0.78
High rates of tuberculosis in patients accessing HAART in rural South Africa. J Acquir Immune Defic Syndr (2014) 0.77
Quarraisha Abdool Karim: investigating HIV/AIDS in South Africa. Interview by Priva Shetty. Lancet (2009) 0.76
Re: "Enhancement of HIV infection by cellulose sulfate," by Tao et al. AIDS Res Hum Retroviruses (2009) 0.76
Measuring adherence by visual inspection of returned empty gel applicators in the CAPRISA 004 microbicide trial. AIDS Behav (2014) 0.76
Scientists stand by decision to join Mbeki's AIDS panel. Nature (2009) 0.75
Adolescent health. S Afr Med J (2015) 0.75
Correction: Features of Recently Transmitted HIV-1 Clade C Viruses that Impact Antibody Recognition: Implications for Active and Passive Immunization. PLoS Pathog (2017) 0.75
Report from the Tenth Retrovirus Conference. Vaccines and microbicides. AIDS Clin Care (2003) 0.75
Case records of the Massachusetts General Hospital. Case 15-2011. A 19-year-old South African woman with headache, fatigue, and vaginal discharge. N Engl J Med (2011) 0.75
Direct questioning of genital symptoms: increasing opportunities for identifying and treating sexually transmitted infections in primary health-care settings. Afr J Reprod Health (2006) 0.75